Stock MRK MERCK & CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:20 2024-09-18 pm EDT 		5-day change 1st Jan Change
118.64 USD +0.30% Intraday chart for Merck & Co., Inc. +3.43% +8.82%
Sep. 18 Merck Secures FDA Approval for Keytruda Combination Therapy as Malignant Pleural Mesothelioma Treatment MT
Sep. 18 Merck Gets First FDA Approval of Keytruda in Malignant Pleural Mesothelioma DJ

Search
See the results
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
100% Free Registration
Daiichi Sankyo - Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
AQ
Merck Secures FDA Approval for Keytruda Combination Therapy as Malignant Pleural Mesothelioma Treatment
MT
Merck Gets First FDA Approval of Keytruda in Malignant Pleural Mesothelioma
DJ
Merck: Keytruda approved for pleural mesothelioma
CF
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
BU
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
CI
Transcript : Merck & Co., Inc. Presents at Bank of America Global Healthcare Conference 2024, Sep-18-2024 10:40 AM
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
DJ
Merck's Lung Cancer Drug Meets Primary Endpoint in Late-Stage Study
MT
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
BU
Merck Says 10-Year Keytruda Phase 3 Trial Results Show Sustained Survival
MT
Merck Says Keytruda With Chemoradiotherapy Lowers Risk of Death in Cervical Cancer Trial
MT
Merck Says Keytruda Combination Improved Overall Survival for Breast Cancer Patients in Phase 3 Trial
MT
Ex-dividend day
FA
Merck Announces the First-Time Presentation of Overall Survival (OS) Results from the Phase 3 KEYNOTE-522 Trial Evaluating KEYTRUDA® (Pembrolizumab)
CI
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
BU
Merck Announces Long-Term Overall Survival Data from the Pivotal Phase 3 KEYNOTE-006 Trial, Evaluating KEYTRUDA® (Pembrolizumab)
CI
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
BU
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
BU
Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW